1. Clinical Trial of Radiotherapy After Intravenous Injection of Acridine Orange for Patients with Cancer.
- Author
-
Kusuzaki K, Takai T, Yoshimura H, Inoue K, Takai S, and Baldini N
- Subjects
- Humans, Mutagens toxicity, Pilot Projects, Treatment Outcome, Acridine Orange therapeutic use, Acridine Orange toxicity, Mutagens therapeutic use, Neoplasms drug therapy, Neoplasms radiotherapy
- Abstract
Aim: We previously found that low-dose X-ray treatment after systemic administration of acridine orange (AO), which is known to have a low toxicity in animals, inhibited tumor growth in experimental studies using mouse osteosarcoma. In this pilot study, we planned to verify the toxicity of intravenous injection of low-dose AO in humans and investigate the anticancer effect of radiation after systemic AO administration (iAOR) for human cancer., Patients and Methods: Eight patients with terminal cancer were treated with iAOR., Results: None of the patients exhibited an adverse effect from AO injection. Three out of the five patients who received a full course of iAOR exhibited clinical or image-based responses, whereas two patients did not., Conclusion: The systemic administration of AO was confirmed not to be toxic in humans, and iAOR was suggested to be potentially effective against radioresistant cancer., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF